Superficial accumulation of plasminogen during plasma clot lysis

Circulation. 1995 Oct 1;92(7):1883-90. doi: 10.1161/01.cir.92.7.1883.

Abstract

Background: Binding of plasminogen to partially degraded fibrin is an important step in fibrinolysis, influencing its rate and fibrin specificity. Little is known about the spatial distribution of plasminogen and of plasminogen-binding sites inside thrombi during lysis. In the present study, we investigated this problem, which is important for a better understanding of the local regulation of fibrinolysis and the rate-limiting factors of therapeutic thrombolysis.

Methods and results: An experimental system was used that allowed continuous visualization and quantification by fluorescence microscopy of the spatial distribution of fluorescein-labeled plasminogen inside and outside model thrombi. Strong superficial accumulation of plasminogen was observed during lysis of a plasma clot induced by tissue-type or urokinase-type plasminogen activators in the surrounding plasma. A distinctly visible plasminogen-accumulating shell moved continuously with the reducing surface of the clot. The accumulation decreased in conditions of exhaustive activation of plasminogen in the outer plasma. It was found in a purified system that a thin superficial layer (approximately 50 microns wide) of a plasmin-treated fibrin clot exposes about 2.5 plasminogen-binding sites per fibrin monomer with a Kd of 2.2 mumol/L. At a physiological concentration of plasminogen (1.5 mumol/L) in the outer medium, plasminogen was concentrated about 10-fold in this layer. The binding was dose-dependently inhibited by epsilon-aminocaproic acid.

Conclusions: We conclude that the generation of potent surface-associated plasminogen-binding sites during thrombolysis results in a strikingly high plasminogen concentration at the dynamically changing surface of a lysing clot. The necessity of a continuous plasminogen supply from the plasma supports the use of fibrin-specific and plasminogen-sparing agents for thrombolytic therapy.

MeSH terms

  • Blood Coagulation / drug effects*
  • Fibrinolysis*
  • Fluorescein-5-isothiocyanate
  • Humans
  • In Vitro Techniques
  • Microscopy, Fluorescence
  • Plasminogen / metabolism*
  • Plasminogen Activators / pharmacology*
  • Tissue Plasminogen Activator / pharmacology*
  • Urokinase-Type Plasminogen Activator / pharmacology*

Substances

  • Plasminogen
  • Plasminogen Activators
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator
  • Fluorescein-5-isothiocyanate